Social Behavior – Page 19

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

1 year ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures

AstraZeneca Appeals IRA Loss, Reiterates Constitutional Challenge to Drug Price Negotiations

1 year ago talkbio0Tagged appeal, AstraZeneca, Constitutional, drug price, Ira (eukaryote), Mediation, Medicare

AstraZeneca, IRA, Medicare, Drug Price Negotiation, Constitutional Challenge, Appeal

Can Element Biosciences Challenge Illumina in the DNA Sequencing Market?

1 year ago talkbio0Tagged ABC, Anabolism, Avidity Base Chemistry, Aviti sequencer, Biotechnology, Cloudbreak, competition, DNA Sequence, Genomics, High-Throughput Nucleotide Sequencing, Illumina, Market, SBS, Sequence Analysis

Element Biosciences, Illumina, DNA sequencing, next-generation sequencing (NGS), Avidity Base Chemistry (ABC), sequencing by synthesis (SBS), Cloudbreak, Aviti sequencer, genomics, biotechnology, market competition

Bristol Myers Squibb Ends Collaboration with Eisai on Antibody-Drug Conjugate Due to Portfolio Prioritization

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Collaboration, ecteribulin, Eisai, farletuzumab, Myers, portfolio, Prioritization, squibb

Bristol Myers Squibb, Eisai, Antibody-Drug Conjugate, Portfolio Prioritization, Collaboration, Farletuzumab Ecteribulin

Merck and Daiichi Sankyo’s ADC Pact Hits Regulatory Setback in FDA Rejection

1 year ago talkbio0Tagged Antibody-Drug Conjugates, Daiichi, Deruxtecan, HER3 protein, Merck, Non-Small Cell Lung Carcinoma, patritumab, Regulatory Setback, Rejection (Psychology), Sankyo, United States Food and Drug Administration

Merck, Daiichi Sankyo, Antibody-Drug Conjugate (ADC), Patritumab Deruxtecan, FDA Rejection, Regulatory Setback, HER3 Protein, Non-Small Cell Lung Cancer (NSCLC)

EU Calls for Cooperation and Increased Manufacturing to Overcome GLP-1 Shortage

1 year ago talkbio0Tagged agonists, cooperation, Diabetes, EU, Glucagon-Like Peptide-1 Receptor, Manufacture, regulatory actions, shortages, Weight maintenance regimen

GLP-1 receptor agonists, EU, shortages, diabetes, weight management, manufacturing, cooperation, regulatory actions

AbbVie’s Duopa Successor in Parkinson’s Rejected Again Due to Third-Party Manufacturer Issues

1 year ago talkbio0Tagged ABBV-951, AbbVie, carbidopa, Duopa, levodopa, Manufacturer Name, Parkinson 's disease, Rejection (Psychology), subcutaneous pump device, third-party, United States Food and Drug Administration

AbbVie, Duopa, Parkinson’s disease, FDA rejection, third-party manufacturer, ABBV-951, carbidopa, levodopa, subcutaneous pump device

CDMO Leaders Unite for Turn-key Drug Production

1 year ago talkbio0Tagged CDMOs, competition, Contract Development, end-to-end services, innovation, Lung consolidation, manufacturing organizations, Market, Pharmaceutical Supply Chain, strategic partnerships, Technology

Contract Development and Manufacturing Organizations (CDMOs), pharmaceutical supply chain, advanced therapies, strategic partnerships, end-to-end services, technology innovation, market consolidation, and competitive advantage.